Zealand Pharma Balance Sheet Health

Financial Health criteria checks 4/6

Zealand Pharma has a total shareholder equity of DKK8.9B and total debt of DKK281.0M, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are DKK9.6B and DKK746.7M respectively.

Key information

3.2%

Debt to equity ratio

DKK 280.99m

Debt

Interest coverage ration/a
CashDKK 8.48b
EquityDKK 8.88b
Total liabilitiesDKK 746.69m
Total assetsDKK 9.63b

Recent financial health updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 22Z's short term assets (DKK8.7B) exceed its short term liabilities (DKK245.6M).

Long Term Liabilities: 22Z's short term assets (DKK8.7B) exceed its long term liabilities (DKK501.1M).


Debt to Equity History and Analysis

Debt Level: 22Z has more cash than its total debt.

Reducing Debt: 22Z's debt to equity ratio has increased from 0% to 3.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 22Z has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 22Z has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies